• Bioregulatory opportunities of Viburkol and Limphomiozot medicines in obstetries and gynecology
To content

Bioregulatory opportunities of Viburkol and Limphomiozot medicines in obstetries and gynecology

HEALTH OF WOMAN. 2016.8(114):41–44; doi 10.15574/HW.2016.114.41 
 

Bioregulatory opportunities of Viburkol and Limphomiozot medicines in obstetries and gynecology


Ostapenko O.

LLC «Institute of family planning», Kyiv


Modern obstetrics and gynecology use a wide range of medicines (drugs) when accompanied by pregnancy and childbirth (miscarriage, discoordination labor, labor pain relief), diseases of the female reproductive system (inflammation, dishormonal disorders, etc.). Among the traditional drugs most widely used antibiotics, NSAIDs, analgesics, antispasmodics, hormones. These drugs, along with the achievement of rapid and pronounced therapeutic effects cause different side effects, and have a number of contra-indications (diseases of the liver, the pancreas, the risk of thrombosis, the development of immunodeficiency, etc.) [12]. In this regard, special attention and care requires the use of drugs in pregnant women and nursing mothers. Also relevant is the increase of efficiency of treatment of many gynecological diseases. All these and many other factors encourage to search for new – more effective and safer treatment approaches and drugs, including pathogenesis [12,22]. The review presents brief characteristics and clinical researches on the use and integrated bioregulatory approach through the use of complex combination bioregulatory medicines (CBM) Viburkol, Limphomiozot, Limphomiozot N in obstetrics and in various diseases and disorders of the female reproductive system [1–3]. The research results show that the inclusion of one or more of the CBM in the traditional treatment help reduce the duration of therapy, a decrease in some side effects, and in some cases rejection of it. In addition, they do not burden for opportunistic diseases, tolerated well and have a favorable safety profile, can be used during pregnancy and lactation [4–22].


Key words: Viburkol, Limphomiozot, Limphomiozot N, bioregulatory approach, combination bioregulatory medicines, obstetrics, gynecology, diseases of the female reproductive system.


REFERENCES

1. Hayne Hartmut. 2004. Znachenie antigomotoksicheskoy terapii v regulyatornoy meditsine. Biologicheskaya meditsina 2:4–9.

2. Klimenko VG. 2013. Osnovnyie polozheniya patogeneticheskogo bioregulyatsionnogo podhoda v obschey terapevticheskoy praktike. Biologicheskaya terapiya 1:8–11.

3. Van Brandt B, Hayne H. 2006. Regulyatornaya blokada: opredelenie, znachenie i terapiya. Biologicheskaya meditsina:4–5.

4. Rekveg G-G. 1997. Gomeopaticheskaya antigomotoksikologiya. Gomeopaticheskaya meditsina. Smolensk:591.

5. Shamugiya BK, Timoshkov MV. 2013. Bioregulyatsionnyiy podhod k lecheniyu boli. Therapia. 2(77):75–78.

6. Vozmozhnosti primeneniya preparata Viburkol v pediatricheskoy, akusherskoy i ginekologicheskoy praktike. Novosti meditsinyi i farmatsii. 2013. 5(449):10–11.

7. Kramarskiy VA, Dudakova VN. 2008. Antigomotoksicheskaya terapiya v profilaktike diskoordinatsii rodovoy deyatelnosti. Biologicheskaya meditsina 2:23–24.

8. Tiraspolskiy IV, Kashirina TN, Busorgina OV, Kuzmin VN, Sovdagarova YuE. 1998. Effektivnost gomeopaticheskih svechey Viburkol pri obezbolivanii rodov. Biologicheskaya meditsina 1:35–38.

9. Manuhin IB, Kashirina TN, Tiraspolskiy IV, Busorgina OV, Hareba LV. 1998. Primenenie gomeopaticheskogo metoda v akusherstve. Metodicheskie rekomendatsii 137/98 MZ Rossii. M:18.

10. Tiraspolskiy IV, Kashirina TN, Busorgina OV, Sovdagarova YuE. 1999. Metodologiya i opyit provedeniya terapii ugrozhayuschego vyikidyisha v pervom trimestre beremennosti kompleksnyimi gomeopaticheskimi preparatami. Biologicheskaya meditsina 1:40–44.

11. Leush SS, Oleynik YuV, Oleynik EA. 2010. Optimizatsiya lecheniya vospalitelnyih zabolevaniy polovyih organov i profilaktika spaechnogo protsessa u zhenschin reproduktivnogo vozrasta. Metodicheskie rekomendatsii MZ Ukrainyi. K:32.

12. Leush SS, Oliinyk YuV. 2006. Antyhomotoksychna terapiia hinekolohichnykh zakhvoriuvan. Metodychni rekomendatsii MOZ Ukrainy. K:30.

13. Chursina TYa, Mihalev KA. 2006. Allopaticheskaya i antigomotoksicheskaya terapiya ostrogo vospaleniya: alternativnyie ili vzaimodopolnyayuschie puti? Biologicheskaya terapiya 1:17–21.

14. Limfomiozot – effektivnyiy limfodrenazhnyiy i protivootechnyiy kompleksnyiy biologicheskiy preparat. Biologicheskaya terapiya. 2013. 1:42–44.

15. Antigomotoksicheskaya terapiya v lechenii hronicheskogo vospaleniya v ginekologii: effektivnost i bezopasnost. Mistetstvo lIkuvannya. 2008. 3(49):58–60.

16. Lahno IV. 2007. Antigomotoksicheskie preparatyi i reproduktivnaya funktsiya zhenschin. Meditsinskie aspektyi zdorovya zhenschinyi 3(6):31–34.

17. Podolskiy VV, Dronova VL, Podolskiy VlV. 2002. Lechenie hronicheskih vospalitelnyih zabolevaniy polovyih organov u zhenschin fertilnogo vozrasta s ispolzovaniem preparatov Gynacoheel i Lymphomyosot. Biologicheskaya terapiya 1:3–7.

18. Parhomenko AP. 2003. Reabilitatsiya reproduktivnoy funktsii zhenschin posle perenesennogo salpingooforita. Avtoref. diss. kand. med. nauk (MZ Ukrainyi). K.

19. Podolskiy VV, Dronova VL, Latyisheva ZM, Teterin VV, Gerevich GY, Teslyuk RS, Fedunov YuS. 2006. Infektsionno-vospalitelnyie protsessyi zhenskih polovyih organov u beremennyih i ih lechenie antigomotoksicheskimi preparatami. Metodicheskie rekomendatsii MZ Ukrainyi. K:26.

20. Tatarchuk TF, Zakharenko NF. 2005. Optymizatsiia metodiv likuvannia khronichnykh endotservikoziv u zhinok, infikovanykh virusom papilomy liudyny. Byolohycheskaia terapyia 4:14–18.

21. Tatarchuk TF, Lyisyanaya TA, Zadorozhnaya TD, Burlaka OV, Korena KO. 2005. SuchasnI osoblivostI lIkuvannya polIpozu endometrIya. Biologicheskaya terapiya 4:34–36.